Skip to main content
NCBI home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2002 Nov 13;3(4):223–243. doi: 10.1016/0924-8579(94)90050-7

Biological response modifiers and infectious diseases: Actual and potential therapeutic agents

James J Rusthoven a,b,∗
PMCID: PMC7135342  PMID: 18611565

Abstract

Biological response modifiers (BRMs) are agents which can modify the immune response to cancer or invasion of the organism by infectious agents. An explosive appearance of new BRMs has resulted from the development of recombinant gene technology and the availability of monoclonal antibodies. Colony-stimulating factors first became available for the prevention of neutropenia but may also have a role in the treatment of infections. Interleukin-1 is being tested as a modular of hematopoiesis and may be useful as a helper factor for T- and B-cell function. Immunoglobulins are being used against viral and bacterial infections while interferons can prevent viral upper respiratory infections and suppress or irradicate some viral hepatitides. Other BRMs which show promise include chemical agents and traditional herbal medicines.

Keywords: Biological response modifiers, Septic shock, Interleukin-1, Colony-stimulating factors, Interferons, Immunoglobulins

References

  • 1.Oldham R.K. Biological response modifiers. J Natl Cancer Inst. 1983;70:789–796. [PubMed] [Google Scholar]
  • 2.Coley W.B. The treatment of inoperable sarcoma with the mixed toxins of erysipelas and Bacillus prodigiousis. Immediate and final results in 140 cases. J Am Med Assoc. 1898;31:389–395. [Google Scholar]; Coley W.B. The treatment of inoperable sarcoma with the mixed toxins of erysipelas and Bacillus prodigiousis. Immediate and final results in 140 cases. J Am Med Assoc. 1898;31:456–465. [Google Scholar]
  • 3.Jaeckle K.A., Mittelman A., Hill F.H. Phase II trial of Serratia marcescens extract in recurrent malignant astrocytoma. J Clin Oncol. 1990;8:1408–1418. doi: 10.1200/JCO.1990.8.8.1408. [DOI] [PubMed] [Google Scholar]
  • 4.Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (Lond.) 1975;256:495–497. doi: 10.1038/256495a0. [DOI] [PubMed] [Google Scholar]
  • 5.Quesada J.R., Hawkins M., Horning S. Cooperative phase I–II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma, and multiple myeloma. Am J Med. 1984;77:427–432. doi: 10.1016/0002-9343(84)90097-4. [DOI] [PubMed] [Google Scholar]
  • 6.Dinarello C.A. Interleukin-1 and the pathogenesis of the acute-phase response. N Engl J Med. 1984;311:1413–1418. doi: 10.1056/NEJM198411293112205. [DOI] [PubMed] [Google Scholar]
  • 7.Ruef C., Coleman D.L. Granulocyte-macrophage colony-stimulating factor: pleotropic cytokine with potential clinical usefulness. Rev Infect Dis. 1990;12:41–62. doi: 10.1093/clinids/12.1.41. [DOI] [PubMed] [Google Scholar]
  • 8.Rusthoven J. The potential role of recombinant hematopoietic colony-stimulating factors in preventing infections in the immunocompromised host. Can J Infect Dis. 1991;2:74–88. doi: 10.1155/1991/782768. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Haranaka K. Traditional Chinese medicines as biological response modifiers. Mol Biother. 1989;1:175–179. [PubMed] [Google Scholar]
  • 10.Bone R.C. The pathogenesis of sepsis. Ann Intern Med. 1991;115:457–469. doi: 10.7326/0003-4819-115-6-457. [DOI] [PubMed] [Google Scholar]
  • 11.Sternberg E.M. mederator. The stress response and the regulation of inflammatory disease. Ann Intern Med. 1992;117:854–866. doi: 10.7326/0003-4819-117-10-854. [DOI] [PubMed] [Google Scholar]
  • 12.Dunn H.A., Powell M.L., Meitin C., Small P.A., Jr. Virus infection as a stressor: the influenza virus elevates plasma concentrations of corticosterone, and brain concentrations of MHPG and tryptophan. Physiol Behav. 1989;45:591–594. doi: 10.1016/0031-9384(89)90078-4. [DOI] [PubMed] [Google Scholar]
  • 13.Edwards C.K., 3rd, Yunger L.M., Lorence R.M., Dantzer R., Kelley K.W. ed 3. Vol. 88. 1991. The pituitary gland is required for protection against lethal effects of Salmonella typhimurium; pp. 2274–2277. (Proc Natl Acad Sci). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Catania A., Manfredi M.G., Airaghi I., Vivirito M.C., Milazzo F., Zanussi C. Evidence of impairment of the immune-adrenal circuit in patients with acquired immunodeficiency syndrome. Horm Metab Res. 1990;22:597–598. doi: 10.1055/s-2007-1004982. [DOI] [PubMed] [Google Scholar]
  • 15.Wilder R. Mechanisms of neuroendocrine effects on inflammation and the immune response. In: Sternberg E.M., editor. moderator. The stress response and the regulation of inflammatory disease. Vol. 117. 1992. pp. 854–866. (Ann Intern Med). [DOI] [PubMed] [Google Scholar]
  • 16.Tazi A., Nioche S., Chastre J., Smiejan J.M., Hance A.J. Spontaneous release of granulocyte colony-stimulating factor (G-CSF) by alveolar macrophages in the course of bacterial pneumonia and sarcoidosis: endotoxin-dependent and exotoxin-independent G-CSF release by cells recovered by bronchoalveolar lavage. Am J Respir Cell Mol Biol. 1991;4:140–147. doi: 10.1165/ajrcmb/4.2.140. [DOI] [PubMed] [Google Scholar]
  • 17.Roilides E., Walsh T.J., Pizzo P.A., Rubin M. Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis. 1991;163:579–583. doi: 10.1093/infdis/163.3.579. [DOI] [PubMed] [Google Scholar]
  • 18.Nelson S., Bagby G., Anderesen J., Shellito J., Summer W. Intratracheal granulocyte colony-stimulating factor enhances systemic and pulmonary host defences. Am Rev Respir Dis. 1991;143:S398. [Google Scholar]
  • 19.Petrak R.A., Balk R.A., Bone R.C. Prostaglandins, cyclo-oxygenase inhibitors, and thromboxane synthetase inhibitors in the pathogenesis of multiple systems organ failure. Crit Care Clin. 1989;5:303–314. [PubMed] [Google Scholar]
  • 20.Balk R.A., Jacobs R.F., Tryka F., Townsend J.W., Walls R.C., Bone R.C. Effects of ibuprofen on neutrophil function and acute lung injury in canine endotoxin schock. Crit Care Clin. 1988;16:1121–1127. doi: 10.1097/00003246-198811000-00008. [DOI] [PubMed] [Google Scholar]
  • 21.Shalaby M.R., Aggarwal B.B., Rinderknect E., Svedersky L.P., Finkle B.S., Palladino M.A., Jr. Activation of human polymor-phonuclear neutrophil functions by interferon-gamma and tumour necrosis factor. J Immunol. 1985;135:2069–2073. [PubMed] [Google Scholar]
  • 22.Lindemann A., Herrmann F., Oster W. Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy. Blood. 1989;74:2644–2651. [PubMed] [Google Scholar]
  • 23.Beutler B., Kronchin N., Milsark I.W., Luedke C., Cerami A. Control of cachectin (tumour necrosis factor) synthesis: mechanisms of endotoxin resistance. Science. 1986;232:977–980. doi: 10.1126/science.3754653. [DOI] [PubMed] [Google Scholar]
  • 24.Dinarello C.A., Cannon J.G., Wolff S.M. New concepts on the pathogenesis of lever. Rev Infect Dis. 1988;10:168–189. doi: 10.1093/clinids/10.1.168. [DOI] [PubMed] [Google Scholar]
  • 25.Butler L.D., Layman N.K., Cain R.L. Interleukin 1-induced pathophysiology: induction of cytokines, development of histopathologic changes, and immunopharmacologic intervention. Clin Immunol Immunopathol. 1989;53:400–421. doi: 10.1016/0090-1229(89)90003-2. [DOI] [PubMed] [Google Scholar]
  • 26.Zuckerman S.H., Shelhaas J., Butler L.D. Differential regulation of lipopolysaccharide-induced interleukin 1 and tumour necrosis factor synthesis: the effects of endogenous gl glucocorticosteroids and the role of pituitary-adrenal access. Eur J Immunol. 1989;19:301–305. doi: 10.1002/eji.1830190213. [DOI] [PubMed] [Google Scholar]
  • 27.Lefer A.M. Induction of tissue injury and altered cardiovascular performance by platelet-activating factor: relevance to multiple systems organ failure. Crit Care Clin. 1989;5:331–351. [PubMed] [Google Scholar]
  • 28.Utsumi K., Takai Y., Tada T. Enhanced production of IL-6 in tumour-bearing mice and determination of cells responsible for its augmented production. J Immunol. 1990;145:397–403. [PubMed] [Google Scholar]
  • 29.Vane J.R., Anggard E.E., Botting R.M. Regulatory functions of the vascular endothelium. N Engl J Med. 1990;323:27–36. doi: 10.1056/NEJM199007053230106. [DOI] [PubMed] [Google Scholar]
  • 30.Dinerman J.L., Mehta J.L. Endothelial, platelet and leukocyte interactions in ischemic heart disease: insights into potential mechanisms and their clinical relevance. J Am Coll Cardiol. 1990;16:207–222. doi: 10.1016/0735-1097(90)90481-4. [DOI] [PubMed] [Google Scholar]
  • 31.Deitch E.A. Multiple organ failure: pathophysiology and potential future therapy. Ann Surg. 1992;216:117–131. doi: 10.1097/00000658-199208000-00002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Arai K., Lee F., Miyajima A. Cytokines: coordinators of immune and inflammatory responses. Annu Rev Biochem. 1990;59:783–836. doi: 10.1146/annurev.bi.59.070190.004031. [DOI] [PubMed] [Google Scholar]
  • 33.Crawford J., Ozer H., Stoller R. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med. 1991;325:164–170. doi: 10.1056/NEJM199107183250305. [DOI] [PubMed] [Google Scholar]
  • 34.Nemunaitis J., Rabinowe S.N., Singer J.W. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med. 1991;324:1773–1778. doi: 10.1056/NEJM199106203242504. [DOI] [PubMed] [Google Scholar]
  • 35.Sheridan W.P., Morstyn G., Wolfe M. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet. 1989;2:891–895. doi: 10.1016/s0140-6736(89)91552-3. [DOI] [PubMed] [Google Scholar]
  • 36.Gianni A.M., Siena S., Bregni M. Granulocyte-macrophage colony-stimulating factor to harvest circulating hemoatopoietic stem cells for autotransplantation. Lancet. 1989;2:580–585. doi: 10.1016/s0140-6736(89)90711-3. [DOI] [PubMed] [Google Scholar]
  • 37.Sheridan W.P., Begley C.G., Juttner C.A. Effective peripheral-blood progenitor cells mobilized by filgrastin (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet. 1992;339:640–644. doi: 10.1016/0140-6736(92)90795-5. [DOI] [PubMed] [Google Scholar]
  • 38.Dale D.C., Hammond W.P., Gabrilove J. Long-term treatment of severe chronic neutropenia with recombinant human granulocyte factor (r-metHuG-CSF) Blood. 1990;76(suppl 1):139. abstract. [Google Scholar]
  • 39.Hammond W.P., Price T.H., Souza L.M., Dale D.C. Treatment of cyclic neutropenia with granulocyte colony-stimulating factor. N Engl J Med. 1989;320:1306–1311. doi: 10.1056/NEJM198905183202003. [DOI] [PubMed] [Google Scholar]
  • 40.Migliaccio A.R., Migliaccio G., Dale D.C., Hammond W.P. Hematopoietic progenitors in cyclic neutropenia: the effect of granulocyte colony-stimulating factor in vivo. Blood. 1990;75:1951–1959. [PubMed] [Google Scholar]
  • 41.Miles S.A., Mitsuyasu R.T., Morano J. Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietic decreases hematologic toxicity from zidovudine. Blood. 1991;77:2109–2117. [PubMed] [Google Scholar]
  • 42.Pluda J.M., Yarchoan R., Smith P.D. Subcutaneous recombinant granulocyte macrophage colony-stimulating factor used as a single agent and in an alternating regimen with azidothymidine in leukopenic patients with severe human immunodeficiency virus infection. Blood. 1990;76:463–472. [PubMed] [Google Scholar]
  • 43.Perno C.F., Yarchoan R., Cooney D.A. Replication of human immunodeficiency virus in monocytes: granulocytes/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3′azido-2′-3′-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine. J Exp Med. 1989;169:933–951. doi: 10.1084/jem.169.3.933. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Nelson S. The effects of thermal injury on systematic and pulmonary host defences. Crit Care Rep. 1991;2:241–253. [Google Scholar]
  • 45.Mooney D.P., Gamelli R.L., O'Reilly M., Hebert J.C. Recombinant human granulocyte colony-stimulating factor and burn Pseudomonas wound sepsis. Arch Surg. 1988;123:1353–1357. doi: 10.1001/archsurg.1988.01400350067010. [DOI] [PubMed] [Google Scholar]
  • 46.Silver G.M., Gamelli R.L., O'Reilly M. The beneficial effect of granulocyte colony-stimulating factory (G-CSF) in combination with gentamycin on survival after Pseudomonas burn wound infection. Surgery. 1989;106:452–456. [PubMed] [Google Scholar]
  • 47.Cairo M.S., Mauss D., Kommareddy S. Prophylactic or simultaneous administration of recombinant human granulocyte colony-stimulating factor in the treatment of group B streptococcal sepsis in neonatal rats. Pediatr Res. 1990;27:612–616. doi: 10.1203/00006450-199006000-00016. [DOI] [PubMed] [Google Scholar]
  • 48.O'Reilly M., Silver G.M., Greenhalgh D., Gamelli R.L., Davis J.H., Hebert J.C. Treatment of intra-abdominal infection with granulocyte colony-stimulating factor. J Trauma. 1992;33:679–682. doi: 10.1097/00005373-199211000-00014. [DOI] [PubMed] [Google Scholar]
  • 49.Hebert J.C., O'Reilly M., Gamelli R.L. Protective effect of recombinant human granulocyte colony-stimulating factor against pneumococcal infections in splenectomized mice. Arch Surg. 1990;125:1075–1078. doi: 10.1001/archsurg.1990.01410200141022. [DOI] [PubMed] [Google Scholar]
  • 50.Nelson S., Summer W., Bagby G. Granulocyte colony-stimulating factor enhances pulmonary host defences in normal and ethanol-treated rats. J Infect Dis. 1991;164:901–906. doi: 10.1093/infdis/164.5.901. [DOI] [PubMed] [Google Scholar]
  • 51.Silberstein D.S., David J.R. The regulation of human eosinophil function by cytokines. Immunol Today. 1987;8:380–384. doi: 10.1016/0167-5699(87)90214-3. [DOI] [PubMed] [Google Scholar]
  • 52.Cheers C., Haigh A.M., Kelso A. Production of colony-stimulating factors during infection: separate determinations of macrophage-, granulocyte-, granulocyte-macrophage-, and multi-CSF's. Infect Immun. 1988;56:247–251. doi: 10.1128/iai.56.1.247-251.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Antman K.S., Griffin J.D., Elias A. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med. 1988;319:593–598. doi: 10.1056/NEJM198809083191001. [DOI] [PubMed] [Google Scholar]
  • 54.Nelson S., Mason C., Bagdy G. Effect of murine recombinant granulocyte-macrophage colony-stimulating factor on lipopolysaccharide-induced tumour necrosis factor. Am Rev Respir Dis. 1990;141:677. S. [Google Scholar]
  • 55.Sisson S.D., Dinarello C.A. Production of interleukin-1 alpha, interleukin-1 beta, and tumour necrosis factor by human mononuclear cells stimulated with granulocyte-macrophage colony-stimulating factor. Blood. 1988;72:1368–1374. [PubMed] [Google Scholar]
  • 56.Atkins E. Pathogenesis of fever. Physiol Rev. 1960;40:580–646. doi: 10.1152/physrev.1960.40.3.580. [DOI] [PubMed] [Google Scholar]
  • 57.Saklatvala J., Sarfield S.J., Townsend Y. Pig interleukin-1: purification of two immunologically different leukocyte proteins that cause cartilage resorption, lymphocyte activation, and fever. J Exp Med. 1985;162:1208–1222. doi: 10.1084/jem.162.4.1208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Dewhirst F.E., Stashenko P.P., Mole J.E., Tsurumachi T. Purification and partial sequence of human osteoclast-activating factor: identity with interleukin-1 beta. J Immunol. 1985;135:2562–2568. [PubMed] [Google Scholar]
  • 59.Moore M.A., Warren D.J. ed 3. Vol. 84. 1987. Synergy of interleukin-1 and granulocyte colony-stimulating factor: in vivo stimulation of stem-cell recovery and hematopoietic regeneration following 5-fluorouracil treatment of mice; pp. 7134–7138. (Proc Natl Acad Sci USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Mori S., Goto K. Cloning and sequence analysis of cDNA for lymphocyte proliferation potentiating factor of rabbit neutrophils: identification as rabbit interleukin-1b. Biochem Biophys Res Comm. 1988;150:1237–1243. doi: 10.1016/0006-291x(88)90761-9. [DOI] [PubMed] [Google Scholar]
  • 61.Fryling C., Dombalagian M., Burgess W. Purification and characterization of tumour inhibitory factor-2: its identity to interleukin-1. Cancer Res. 1989;49:3333–3337. [PubMed] [Google Scholar]
  • 62.Dinarello C.A. Interleukin-1 and interleukin-1 antagonism. Blood. 1991;77:1627–1652. [PubMed] [Google Scholar]
  • 63.Fibbe W.E., Schaafsma R., Falkenburg J.H.F., Willemze R. The biological activities of interleukin-1. Blut. 1989;59:147–156. doi: 10.1007/BF00320059. [DOI] [PubMed] [Google Scholar]
  • 64.Dinarello C.A., Ikejima T., Warner S.J. Interleukin-1 induces interleukin. I. Induction of circulating interleukin-1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol. 1987;139:1902–1910. [PubMed] [Google Scholar]
  • 65.Warner S.J.C., Auger K.R., Libby P. Interleukin-1 induces interleukin-1. II. Interleukin-1 induces production of interleukin-1 by adult human vascular endothelial cells in vitro. J Immunol. 1987;139:1911–1917. [PubMed] [Google Scholar]
  • 66.Sisson S.D., Dinarello C.A. Production of interleukin-1 alpha, interleukin-1 beta and tumour necrosis factor by human mononuclear cells stimulated with granulocyte-macrophage colony-stimulating factor. Blood. 1990;75:1895–1896. [PubMed] [Google Scholar]
  • 67.Dinarello C.A., Cannon J.G., Wolff S.M. Tumour necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin-1. J Exp Med. 1986;163:1433–1450. doi: 10.1084/jem.163.6.1433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Ghezzi P., Dinarello C.A. IL-1 induces IL-1. III. Specific inhibition of IL-1 production by IFN-gamma. J Immunol. 1988;140:4238–4244. [PubMed] [Google Scholar]
  • 69.Moore K.W., Vieira P., Fiorentino D.F. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science. 1990;248:1230–1234. doi: 10.1126/science.2161559. [DOI] [PubMed] [Google Scholar]
  • 70.Smith J., Urba W., Steis R. Interleukin-1 alpha: results of a phase I toxicity and immunomodulatory trial. Am Soc Clin Oncol. 1990;9:717. [Google Scholar]
  • 71.Tewari A., Buhles W.C., Jr., Stranes H.F., Jr. Preliminary report: effects of interleukin-1 on platelet counts. Lancet. 1990;336:712–714. doi: 10.1016/0140-6736(90)92206-w. [DOI] [PubMed] [Google Scholar]
  • 72.Neta R., Douches S.D., Oppenheim J.J. Interleukin-1 as a radioprotector. J Immunol. 1986;136:2483–2485. [PubMed] [Google Scholar]
  • 73.Fibbe W.E., Van der Meer J.W.M., Falkenburg J.H.F. A single low dose of human recombinant interleukin-1 accelerates the recovery of neutrophils in mice with cyclophosphamide-induced neutropenia. Exp Haematol. 1989;17:229–234. [PubMed] [Google Scholar]
  • 74.Van der Meer J.W.M., Barza M., Wolff S.M., Dinarello C.A. ed 3. Vol. 85. 1988. A low dose of recombinant interleukin-1 protects granulocytopenic mice from lethal Gram-negative infection; pp. 1620–1623. (Proc Natl Acad Sci USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Fibbe W.E., Falkenburg J.H.F., Schaafsma M.R., Willemze R. The hematopoietic activities of interleukin-1. Biotherapy. 1989;1:263–271. doi: 10.1007/BF02171002. [DOI] [PubMed] [Google Scholar]
  • 76.McNiece I., Langely K., Zsebo K. Recombinant human stem cell factor synergizes with CSF's and EPO to stimulate colony formulation of myeloid and erythroid cells. Blood. 1990;76:154a. (Abstr suppl) [Google Scholar]
  • 77.Neta R., Sztein M.B., Oppenheim J.J. The in vivo effects of interleukin-1. Bone marrow cells are induced to cycle after administration of interleukin-1. J Immunol. 1987;139:1861–1866. [PubMed] [Google Scholar]
  • 78.Gasparetto C., Laver J., Abboud M. Effect of interleukin-1 on hematopoietic progenitors: evidence of stimulatory and inhibitory activities in a primate model. Blood. 1989;74:547–550. [PubMed] [Google Scholar]
  • 79.Wallach D., Holtmann H., Engelmann H., Nophar Y. Sensitization and desensitization to lethal effects of tumour necrosis factor and IL-1. J Immunol. 1988;140:2994–2999. [PubMed] [Google Scholar]
  • 80.Ye K., Koch K.C., Clark B.D., Dinarello C.A. Interleukin-1 beta down regulates gene and surface expression of interleukin-1 receptor type I by destabilizing its mRNA whereas interleukin-2 increases its expression. Immunology. 1992;75:427–434. [PMC free article] [PubMed] [Google Scholar]
  • 81.Mrosovsky N., Molony L.A., Conn C.A., Kluger M.J. Anorexic effects of interleukin-1 in the rat. Am J Physiol. 1989;257:R1315. doi: 10.1152/ajpregu.1989.257.6.R1315. [DOI] [PubMed] [Google Scholar]
  • 82.Gershenwald J.E., Fong Y.M., Fahey T.J., III . ed 3. Vol. 87. 1990. Interleukin-1 receptor blockade attenuates the host inflammatory response; pp. 4966–4970. (Proc Natl Acad Sci USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Okusawa S., Gelfand J.A., Ikejima T. Interleukin-1 induces a shock-like state in rabbits. Synergism with tumour necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest. 1988;81:1162–1172. doi: 10.1172/JCI113431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Rothenberg E.V., Diamond R.A., Pepper K.A., Yang J.A. IL-2 inducibility in T cells before T cell receptor expression. J Immunol. 1990;144:1614–1624. [PubMed] [Google Scholar]
  • 85.Kurt-Jones E.A., Beller D.I., Mizel S.B. ed 3. Vol. 82. 1985. Identification of a membrane-associated interleukin-1 in macrophages; pp. 1204–1208. (Proc Natl Acad Sci USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Fong Y., Tracey K.J., Moldawer L.L. Antibodies to cachetin/tumour necrosis factor reduce interleukin-1 beta and interleukin-6 appearance during lethal bacteremia. J Exp Med. 1989;170:1627–1633. doi: 10.1084/jem.170.5.1627. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Neta R., Oppenheim J.J., Douches S.D. Interdependence of radioprotective effects of human recombinant interleukin-1 alpha, tumour necrosis factor alpha, granulocyte colony-stimulating factor, and murine recombinant granulocyte-macrophage colony stimulating factor. J Immunol. 1988;140:108–111. [PubMed] [Google Scholar]
  • 88.Chantry D., Turner M., Abney E., Feldman M. Modulation of cytokine production by transforming growth factor-beta. J Immunol. 1989;142:40–95. [PubMed] [Google Scholar]
  • 89.Moreb J., Zucali J.R., Weiner R.S. The role of interleukin-3 and interleukin-6 and the protection from 4-hydroperoxy cyclophosphamide and the proliferation of early human hematopoietic progenitor cells. Exp Hematol. 1989;17:1022–1027. [PubMed] [Google Scholar]
  • 90.Dinarello C.A., Rosenwasser L.J., Wolff S.M. Demonstration of circulating supressor factor of thymocyte proliferation during endotoxin fever in humans. J Immunol. 1981;127:2517–2519. [PubMed] [Google Scholar]
  • 91.Liao Z., Grimshaw R.S., Rosenstreich D.L. Identification of a specific interleukin-1 inhibitor in the urine of febrile patients. J Exp Med. 1984;159:126–136. doi: 10.1084/jem.159.1.126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92.Seckinger P., Dayer J.M. Interleukin-1 inhibitors. Ann Inst Pasteur Immunol. 1987;138:486–488. doi: 10.1016/s0769-2625(87)80063-6. [DOI] [PubMed] [Google Scholar]
  • 93.Balavoine J.F., De Rochemonteix B., Williamson K. Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin-1 and inhibitor(s) J Clin Invest. 1986;78:1120–1124. doi: 10.1172/JCI112669. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94.Ohlsson K., Bjork P., Bergenfeldt M. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature. 1990;348:550–552. doi: 10.1038/348550a0. [DOI] [PubMed] [Google Scholar]
  • 95.Cominelli F., Nast C.C., Clark B.D. Interleukin-1 gene expression, synthesis and effective specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest. 1990;86:972–980. doi: 10.1172/JCI114799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.Ziegler E.J., McCutchan J.A., Fierer J. Treatment of Gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med. 1982;307:1225–1230. doi: 10.1056/NEJM198211113072001. [DOI] [PubMed] [Google Scholar]
  • 97.Baumgartner J.-D., Glauser M.P., McCutchan J.A. Prevention of Gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet. 1985;2:59–63. doi: 10.1016/s0140-6736(85)90176-x. [DOI] [PubMed] [Google Scholar]
  • 98.Cornelissen J.J., Van Kessel C.P., Brouwer E., Kraaijeveld C.A., Verhoef J. Inhibition of lipid A-specific monoclonal antibodies by priming of human polymorphonuclear leucocytes by endotoxin. J Med Microbiol. 1991;34:233–238. doi: 10.1099/00222615-34-4-233. [DOI] [PubMed] [Google Scholar]
  • 99.Burd R.S., Cody C.S., Raymond C.S., Dunn D.L. Anti-endotoxin monoclonal antibodies protect by enhancing bacterial and endotoxin clearance. Arch Surg. 1993;128:145–150. doi: 10.1001/archsurg.1993.01420140022004. [DOI] [PubMed] [Google Scholar]
  • 100.Krieger J.I., Fletcher R.C., Siegel S.A. Human anti-endotoxin antibody HA-1A mediates complement-dependent binding of Escherichia coli J5 lipopolysaccharide to complement receptor type 1 of human erythrocytes and neutrophils. J Infect Dis. 1993;167:865–875. doi: 10.1093/infdis/167.4.865. [DOI] [PubMed] [Google Scholar]
  • 101.Cody C.S., Burd R.S., Mayoral J.L., Dunn D.L. Protective anti-lipopolysaccharide monoclonal antibodies inhibits tumour necrosis factory production. J Surg Res. 1992;52:314–319. doi: 10.1016/0022-4804(92)90109-d. [DOI] [PubMed] [Google Scholar]
  • 102.Wortel C.H., von der Mohlen M.A., van Deventer S.J. Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in Gram-negative sepsis: relationship to endotoxin and cytokine levels. J Infect Dis. 1992;166:1367–1374. doi: 10.1093/infdis/166.6.1367. [DOI] [PubMed] [Google Scholar]
  • 103.McCabe W.R., De Maria A., Jr., Berberich H., Johns M.A. Immunization with rough mutants of Salmonella minnesota: protective activity of IgM and IgG antibody to the R595 (RE chemotype) mutant. J Infect Dis. 1988;158:291–300. doi: 10.1093/infdis/158.2.291. [DOI] [PubMed] [Google Scholar]
  • 104.Teng N.N.H., Kaplan H.S., Hebert J.M. ed 3. Vol. 82. 1985. Protection against Gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies; pp. 1790–1794. (Proc Natl Acad Sci USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 105.Siegel S.A., Evans M.E., Pollack M. Antibiotics enhanced binding by human lipid A-reactive monoclonal antibody HA-1A to smooth Gram-negative bacteria. Infect Immun. 1993;61:512–519. doi: 10.1128/iai.61.2.512-519.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106.Ziegler E.J., Teng N.N.H., Douglas H. Treatment of pseudomonas bacteremia in neutropenic rabbits with human monoclonal IgM antibody against E. coli lipid A. Clin Res. 1987;35:619A. abstract. [Google Scholar]
  • 107.Ziegler E.J. Protective antibody to endotoxin core: the emperor's new clothes? J Infect Dis. 1988;158:286–290. doi: 10.1093/infdis/158.2.286. [DOI] [PubMed] [Google Scholar]
  • 108.Quezado Z.M., Natanson C., Alling D.W. A controlled trial of HA-1A in a canine model of Gram-negative septic shock. JAMA. 1993:2221–2227. [PubMed] [Google Scholar]
  • 109.Calandra T., Glauser M.P., Schellekens J., Verhoef J. Treatment of Gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective double-blind randomized trial. J Infect Dis. 1988;158:312–319. doi: 10.1093/infdis/158.2.312. [DOI] [PubMed] [Google Scholar]
  • 110.Khazaeli M.B., Wheeler R., Teng N. Initial evaluation of a human immunoglobulin M monoclonal antibody (HA-1A) in humans. J Biol Response Mod. 1990;9:178–184. [PubMed] [Google Scholar]
  • 111.Fisher C.J., Jr., Zimmerman J., Khazaeli M.B. Initial evaluation of human monoclonal anti-lipid A antibody (HA-1A) in patients with sepsis syndrome. Crit Care Med. 1990;18:1311–1315. doi: 10.1097/00003246-199012000-00001. [DOI] [PubMed] [Google Scholar]
  • 112.Ziegler E.J., Fisher C.J., Sprung C.L. Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. N Engl J Med. 1991;324:429–436. doi: 10.1056/NEJM199102143240701. [DOI] [PubMed] [Google Scholar]
  • 113.Siegel J.P., Stein K.E., Zoon K.C. Anti-endotoxin monoclonal antibodies. N Engl J Med. 1992;327:890–891. [Google Scholar]
  • 114.Wolff S.M. Monoclonal antibodies and the treatment of Gram-negative bacteremia and shock. N Engl J Med. 1991;324:486–487. doi: 10.1056/NEJM199102143240709. [DOI] [PubMed] [Google Scholar]
  • 115.Tanio C.P., Feldman H.I. The HA-1A monoclonal antibody for Gram-negative sepsis (letter) N Engl J Med. 1991;324:280. doi: 10.1056/NEJM199107253250411. [DOI] [PubMed] [Google Scholar]
  • 116.Schulman K.A., Glick H.A., Reuben H., Eisenberg J.M. Cost-effectiveness of HA-1A monoclonal antibody for Gram-negative sepsis. Economic assessment of a new therapeutic agent. JAMA. 1991;266:3466–3471. [PubMed] [Google Scholar]
  • 117.Greenman R.L., Schein R.M., Martin M.A. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. The XOMA Sepsis Study Group. JAMA. 1991;266:1097–1102. [PubMed] [Google Scholar]
  • 118.Romulo R.L., Palardy J.E., Opal S.M. Efficacy of anti-endotoxin monoclonal antibody E5 alone or in combination with ciprofloxacin in neutropenic rats with Pseudomonas sepsis. J Infect Dis. 1993;167:126–130. doi: 10.1093/infdis/167.1.126. [DOI] [PubMed] [Google Scholar]
  • 119.Wenzel R.P., Andriole V.T., Bartlett J.G. Antiendotoxin monoclonal antibodies for Gram-negative sepsis: guidelines from the IDSA. Clin Infect Dis. 1992;14:973–976. doi: 10.1093/clinids/14.4.973. [DOI] [PubMed] [Google Scholar]
  • 120.ed 3. Vol. 8. Department of Health and Human Services; Bethesda, MD: 1990. Intravenous immunoglobulin: prevention and treatment of disease. (NIH Consensus Development Conference. Consensus statement, May 21–23, 1990). No. 5. [PubMed] [Google Scholar]
  • 121.Eibl M.M., Wedgwood R.J. Intravenous immunoglobulin: a review. Immunodefic Rev. 1989;1:1–42. (Suppl) [PubMed] [Google Scholar]
  • 122.Lundblad J.L., Mitra G., Sternberg M.M., Schroeder D.D. Comparative studies of impurities in intravenous immunoglobulin preparations. Rev Infect Dis. 1986;8:S382–S390. doi: 10.1093/clinids/8.supplement_4.s382. [DOI] [PubMed] [Google Scholar]
  • 123.Zubler R.H. Antibody feedback regulation of the humoral immune response. In: Nydegger U.E., editor. Immunochemotherapy: a guide to immunoglobulin prophylaxis and therapy. Academic Press; New York: 1981. pp. 65–74. [Google Scholar]
  • 124.Dwter J.M. Manipulating the immune system with immunoglobulin. N Engl J Med. 1992;326:107–116. doi: 10.1056/NEJM199201093260206. [DOI] [PubMed] [Google Scholar]
  • 125.Fehr J., Hofmann V., Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gammaglobulin. N Engl J Med. 1982;306:1254–1258. doi: 10.1056/NEJM198205273062102. [DOI] [PubMed] [Google Scholar]
  • 126.Delfraissy J.F., Tchernia G., Laurian Y. Suppressor cell function after intravenous gammaglobulin treatment in adult chronic idiopathic thrombocytopenic purpura. Br J Haematol. 1985;60:315–322. doi: 10.1111/j.1365-2141.1985.tb07417.x. [DOI] [PubMed] [Google Scholar]
  • 127.Bussel J., Pahwa S., Porges A. Correlation of in vitro antibody synthesis with outcome of intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. J Clin Immunol. 1986;6:50–56. doi: 10.1007/BF00915364. [DOI] [PubMed] [Google Scholar]
  • 128.Abdou M.I., Wall H., Lindsley H.B. Network theory in autoimmunity: in vitro suppression of serum anti-DNA antibody binding to DNA by antibody-ideotypic antibody in systemic lupus erythematosus. J Clin Invest. 1981;67:1297–1304. doi: 10.1172/JCI110158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 129.Bijsterbosch M.K., Klaus G.G.B. Cross-linking of surface immunoglobulin and Fc receptors on B-lymphocytes inhibits stimulation of inositol phospholipid breakdown via the antigen receptors. J Exp Med. 1985;162:1825–1836. doi: 10.1084/jem.162.6.1825. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 130.Hahn B.H., Ebling R.M. Suppression of murine lupus nephritis by administration of an anti-idiotypic antibody of anti-DNA. J Immunol. 1984;132:187–190. [PubMed] [Google Scholar]
  • 131.Furusho K., Kamiya T., Nakano H. High-dose intravenous gamma-globulin for Kawasaki disease. Lancet. 1984;2:1055–1058. doi: 10.1016/s0140-6736(84)91504-6. [DOI] [PubMed] [Google Scholar]
  • 132.Newburger J.W., Takahashi M., Burns J.C. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986;315:341–347. doi: 10.1056/NEJM198608073150601. [DOI] [PubMed] [Google Scholar]
  • 133.Lekova E.S., Joffe L., Glode M.P. Antigenic recognition by intravenous gamma-globulin of selected bacteria isolated from throats of patients with Kawasaki syndrome. Pediatr Infect Dis J. 1990;9:620–623. [PubMed] [Google Scholar]
  • 134.Leung D.Y.M., Burns J.C., Newburger J.W., Geha R.S. Reversal of lymphocytes activation in vivo in Kawasaki syndrome by intravenous gamma-globulin. J Clin Invest. 1987;79:468–472. doi: 10.1172/JCI112835. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 135.Winston D.J., Pollard R.B., Ho W.G. Cytomegalovirus immune plasma in bone marrow transplant recipients. Ann Intern Med. 1982;97:11–18. doi: 10.7326/0003-4819-97-1-11. [DOI] [PubMed] [Google Scholar]
  • 136.Condie R.M., O'Reilly R.J. Prevention of cytomegalovirus infection by prophylaxis with an intravenous hyperimmune, native, unmodified cytomegalovirus globulin. Am J Med. 1984;76:134–141. doi: 10.1016/0002-9343(84)90332-2. [DOI] [PubMed] [Google Scholar]
  • 137.Meyers J.D., Leszczynski J., Zaia J.A. Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. Ann Intern Med. 1983;98:442–446. doi: 10.7326/0003-4819-98-4-442. [DOI] [PubMed] [Google Scholar]
  • 138.Bowden R.A., Sayers M., Flournoy M. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med. 1986;314:1006–1010. doi: 10.1056/NEJM198604173141602. [DOI] [PubMed] [Google Scholar]
  • 139.Emanuel D., Cunningham I., Jules-Elysee K. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with a combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med. 1988;109:777–782. doi: 10.7326/0003-4819-109-10-777. [DOI] [PubMed] [Google Scholar]
  • 140.Read E.C., Bowden R.A., Dandliker P.S. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med. 1988;109:783–788. doi: 10.7326/0003-4819-109-10-783. [DOI] [PubMed] [Google Scholar]
  • 141.Sullivan K.M., Kopecky K.J., Jocom A. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med. 1990;323:705–712. doi: 10.1056/NEJM199009133231103. [DOI] [PubMed] [Google Scholar]
  • 142.Snydman D.R., Werner B.G., Heinze-Lacey B. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med. 1987;317:1049–1054. doi: 10.1056/NEJM198710223171703. [DOI] [PubMed] [Google Scholar]
  • 143.Graneto D., Swift C., Steinmuller D.R. Use of intravenous immunoglobulin prophylaxis for primary cytomegalovirus (CMV) infection post-living-related donor renal transplantation (abstract 10). Abstracts of the American Society of Transplant Physicians Annual Meeting; Chicago; 1988. [PubMed] [Google Scholar]
  • 144.Lederman H.M., Winkelstein J.A. X-linked agammaglobulinemia: an analysis of 96 patients. Medicine (Baltimore) 1985;64:145–156. [PubMed] [Google Scholar]
  • 145.Calvelli D.A., Rubinstein A. Intravenous gammaglobulin in infant acquired immunodeficiency syndrome. Pediatr Infect Dis. 1986;5:S207. [PubMed] [Google Scholar]
  • 146.Siegel F.P., Oleske J. Management of the acquired immune deficiency syndrome: is there a role for immune globulins? In: Morell A., Nydegger U.E., editors. Clinical use of intravenous immunoglobulins. Academic Press; New York: 1986. pp. 387–394. [Google Scholar]
  • 147.Schaad U.B. The role of IVIG in pediatric HIV infection. In: Imbach P., editor. Immunotherapy with intravenous immunoglobulins. Academic Press; London: 1991. pp. 201–209. [Google Scholar]
  • 148.The National Institute of Child Health and Human Development Intravenous Immunoglobulin Study Group Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N Engl J Med. 1991;325:73–80. doi: 10.1056/NEJM199107113250201. [DOI] [PubMed] [Google Scholar]
  • 149.Paryani S.G., Arvin A.M., Koropchak C.M. Comparison of varicella-zoster antibody titers in patients given intravenous immune serum globulin or varicella-zoster immune globulin. J Pediatr. 1984;105:200–205. doi: 10.1016/s0022-3476(84)80113-4. [DOI] [PubMed] [Google Scholar]
  • 150.Stevens D.A., Merigan T.C. Zoster immune globulin prophylaxis of disseminated zoster in compromised hosts. Arch Intern Med. 1980;140:52. [PubMed] [Google Scholar]
  • 151.Hemming V.G., Rodriguez W., Kim H.W. Intravenous immunoglobulin treatment of respiratory syncytical virus infections in infants and young children. Antimicrob Agents Chemother. 1987;31:1882–1886. doi: 10.1128/aac.31.12.1882. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 152.Crennan J.M., Van Scoy R.E., McKenna C.H., Smith T.F. Echovirus polymyositis in patients with hypogammaglobulinemia. Failure of high-dose intravenous gammaglobulin therapy and review of the literature. Am J Med. 1986;81:35–42. doi: 10.1016/0002-9343(86)90179-8. [DOI] [PubMed] [Google Scholar]
  • 153.Tobi M., Straus S.E. Chronic Epstein-Barr virus disease: a workshop held by the National Institute of Allergy and Infectious Diseases. Ann Intern Med. 1985;103:951–952. doi: 10.7326/0003-4819-103-6-951. [DOI] [PubMed] [Google Scholar]
  • 154.Lloyd A., Hickie I., Wakefield D. A double-blind placebo-controlled trial of intravenous immunoglobulin therapy patients with chronic fatigue syndrome. Am J Med. 1990;89:561–566. doi: 10.1016/0002-9343(90)90173-b. [DOI] [PubMed] [Google Scholar]
  • 155.Peterson P.K., Shepard J., Macres M. A controlled trial of intravenous immunoglobulin G in chronic fatigue syndrome. Am J Med. 1990;89:554–560. doi: 10.1016/0002-9343(90)90172-a. [DOI] [PubMed] [Google Scholar]
  • 156.Ammann A.J., Hong R. Disorders of the T-cell system. In: Stiehm E.R., editor. Immunologic disorders in infants and children. ed 3. WB Saunders Co; Philadelphia: 1989. pp. 257–315. [Google Scholar]
  • 157.Sidiropoulos D., Boehme U., Von Muralt G. Immunoglobulin supplementation in prevention or treatment of neonatal sepsis. Pediatr Infect Dis. 1986;5:S193. [PubMed] [Google Scholar]
  • 158.Haque K.N., Zaidi M.H., Bahakim H. IgM-enriched intravenous immunoglobulin therapy in neonatal sepsis. Am J Dis Child. 1988;142:1293–1296. doi: 10.1001/archpedi.1988.02150120047038. [DOI] [PubMed] [Google Scholar]
  • 159.Munter A.M., Hoagland H.C., Pruitt B.A., Jr. The effect of thermal injury on serum immunoglobulins. Ann Surg. 1970;172:965–969. doi: 10.1097/00000658-197012000-00006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 160.Wesley J., Fisher M.W. Immunization against Pseudomonas in infection after thermal injury. J Infect Dis. 1974;130:S152–S158. doi: 10.1093/infdis/130.supplement.s152. [DOI] [PubMed] [Google Scholar]
  • 161.Stone H.H., Graber C.D., Martin J.D., Jr., Kolb L. Evaluation of a gamma globulin for prophylaxis against burn sepsis. Surgery. 1965;58:810–814. [PubMed] [Google Scholar]
  • 162.Munster A.M., Moran K.T., Thupari J. Prophylactic intravenous immunoglobulin replacement in high-risk burn patients. J Burn Care Rehabil. 1987;8:376–380. doi: 10.1097/00004630-198709000-00007. [DOI] [PubMed] [Google Scholar]
  • 163.Winnie J.B., Cowan R.G., Wade N.A. Intravenous immune globulin treatment of pulmonary exacerbations in cystic fibrosis. J Pediatr. 1989;114:309–314. doi: 10.1016/s0022-3476(89)80804-2. [DOI] [PubMed] [Google Scholar]
  • 164.Van Wye J.E., Collins M.S., Baylor M. Pseudomonas hyperimmune globulin passive immunotherapy for pulmonary exacerbations of cystic fibrosis. Pediatr Pulmonol. 1990;9:7–18. doi: 10.1002/ppul.1950090104. [DOI] [PubMed] [Google Scholar]
  • 165.Silverstein A. History of immunology. Antibodies and anti-idiotypic regulation, 1899–1904. Cell Immunol. 1986;99:507. doi: 10.1016/0008-8749(86)90258-3. [DOI] [PubMed] [Google Scholar]
  • 166.Kunkel H.G., Mannik M., Williams R.C. Individual antigenic specificity of isolated antibodies. Science. 1963;140:1218–1219. doi: 10.1126/science.140.3572.1218. [DOI] [PubMed] [Google Scholar]
  • 167.Jerne N.K. Towards a network theory of the immune system. Ann Immunol (Paris) 1974;125C:373–389. [PubMed] [Google Scholar]
  • 168.Nisonoff A., Lamoyi E. Implications of the presence of an internal image of the antigen in anti-idiotypic antibodies; possible application to vaccine production. Clin Immunol Immunopathol. 1981;21:397–406. doi: 10.1016/0090-1229(81)90228-2. [DOI] [PubMed] [Google Scholar]
  • 169.Roitt I.M., Male D.K., Guarnotta L.D. Idiotypic networks and their possible exploitation for manipulation of the immune response. Lancet. 1981;1:1041–1045. doi: 10.1016/s0140-6736(81)92199-1. [DOI] [PubMed] [Google Scholar]
  • 170.Nisonoff A. Idiotypes: concepts and applications. J Immunol. 1991;147:2429–2438. [PubMed] [Google Scholar]
  • 171.Kennedy R.C., Eichberg J.W., Lanford R.E., Dreesman J.R. Anti-idiotypic antibody vaccine for type-B viral hepatitis in chimpanzees. Science. 1986;232:220–223. doi: 10.1126/science.3952505. [DOI] [PubMed] [Google Scholar]
  • 172.Thanavala Y.M., Roitt I.M. Monoclonal anti-idiotypic antibodies as surrogates for hepatitis B surface antigen. Int Rev Immunol. 1986;1:27–39. doi: 10.3109/08830188609056599. [DOI] [PubMed] [Google Scholar]
  • 173.Reagan K.J., Wunner W.H., Wiktor T.J., Koprowski H. Anti-idiotypic antibodies induce neutralizing antibodies to rabies virus glycoprotein. J Virol. 1983;48:660–666. doi: 10.1128/jvi.48.3.660-666.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 174.Gaulton G.M., Greene M.I. Idiotypic mimicry of biological receptors. Annu Rev Immunol. 1986;4:253–280. doi: 10.1146/annurev.iy.04.040186.001345. [DOI] [PubMed] [Google Scholar]
  • 175.Rolf J.M., Gauden H.M., Tirrell S.M., MacDonald A.B., Eidels L. Vol. 86. 1989. Anti-idiotypic antibodies that protect cells against the action of diphtheria toxin; p. 2036. (Proc Natl Acad Sci USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 176.Rimmelzwaan G.F., Bunschoten E.J., Uytdehaag F.G., Osterhaus A.D. Monoclonal anti-idiotypic antibody vaccines against poliovirus, canine parvovirus and rabies virus. Methods Enzymol. 1989;178:375–390. doi: 10.1016/0076-6879(89)78028-9. [DOI] [PubMed] [Google Scholar]
  • 177.Zaghouani H., Goldstein D., Shah H. Vol. 88. 1991. Induction of antibodies to the envelope protein of the human immunodeficiency virus by immunization with monoclonal anti-idiotypes; pp. 5645–5649. (Proc Natl Acad Sci USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 178.Merigan T.C., Reed S.E., Hall T.S., Tyrrell D.A.J. Inhibition of respiratory virus infection by locally applied interferon. Lancet. 1973;1:563–567. doi: 10.1016/s0140-6736(73)90714-9. [DOI] [PubMed] [Google Scholar]
  • 179.Scott G.M., Phillpotts R.J., Wallace J., Gauci C.L., Greiner J., Tyrrell D.A. Prevention of rhinovirus colds by human interferon-alpha2 from Escherichia coli. Lancet. 1982;2:186–188. doi: 10.1016/s0140-6736(82)91031-5. [DOI] [PubMed] [Google Scholar]
  • 180.Higgins P.G., Phillpotts R.J., Scott G.M., Wallace J., Bernhardt L.L., Tyrrell D.A.J. Intranasal interferon as protection against experimental respiratory Corona virus infection in volunteers. Antimicrob Agents Chemother. 1983;24:713–715. doi: 10.1128/aac.24.5.713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 181.Douglas R.M., Albrecht J.K., Miles H.B. Intrasanal interferon alpha-2 prophylaxis of natural respiratory infection. J Infect Dis. 1985;151:731–736. doi: 10.1093/infdis/151.4.731. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 182.Hayden F.G., Gwaltney J.M., Jr., Johns E.M. Prophylactic efficacy and tolerance of low-dose intranasal interferon-alpha2 in natural respiratoty viral infections. Antiviral Res. 1985;5:111–116. doi: 10.1016/0166-3542(85)90037-3. [DOI] [PubMed] [Google Scholar]
  • 183.Hayden F.G., Albrecht J.K., Kaiser D.L., Gwaltney J.M., Jr. Prevention of natural colds by contact prophylaxus with intranasal alpha2-interferon. N Engl J Med. 1986;314:71–75. doi: 10.1056/NEJM198601093140202. [DOI] [PubMed] [Google Scholar]
  • 184.Douglas R.M., Moore B.W., Miles H.B. Prophylactic efficacy of intranasal alpha2-interferon against rhinovirus infections in the family setting. N Engl J Med. 1986;314:65–70. doi: 10.1056/NEJM198601093140201. [DOI] [PubMed] [Google Scholar]
  • 185.Merigan T.C., Jordan G.W., Fried R.P. Clinical utilization of exogenous human interferon. In: Pollard M., editor. Vol. 9. Academic Press; New York: 1975. pp. 249–264. (Antiviral Mechanisms (Perspectives in Virology)). [Google Scholar]
  • 186.Greenberg H.B., Pollard R.B., Lutwick L.I., Gregory P.B., Robinson W.S., Merigan T.C. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med. 1976;295:517–522. doi: 10.1056/NEJM197609022951001. [DOI] [PubMed] [Google Scholar]
  • 187.Jordan G.W., Fried R.P., Merigan T.C. Administration of human leukocyte interferon in herpes zoster I safety circulating antiviral activity, and host responses to infection. J Infect Dis. 1974;130:56–62. doi: 10.1093/infdis/130.1.56. [DOI] [PubMed] [Google Scholar]
  • 188.Hoofnagle J.H., Peters M., Mullen K.D. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology. 1988;95:1318–1325. doi: 10.1016/0016-5085(88)90367-8. [DOI] [PubMed] [Google Scholar]
  • 189.Perrillo R.P., Schiff E.R., Davis G.L. A randomized, controlled trial of interferon alpha-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med. 1990;323:295–301. doi: 10.1056/NEJM199008023230503. [DOI] [PubMed] [Google Scholar]
  • 190.Bisceglie A.M., Martin P., Kassianides C. Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989;321:1506–1510. doi: 10.1056/NEJM198911303212204. [DOI] [PubMed] [Google Scholar]
  • 191.Davis G.L., Balart L.A., Schiff E.R. Treatment of chronic hepatitis C with recombinant interferon alpha. A multicentre randomized, controlled trial. N Engl J Med. 1989;321:1501–1506. doi: 10.1056/NEJM198911303212203. [DOI] [PubMed] [Google Scholar]
  • 192.Lane H.C., Davey V., Kovacs J.A. Interferon-α in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial. Ann Intern Med. 1990;112:805–811. doi: 10.7326/0003-4819-112-11-805. [DOI] [PubMed] [Google Scholar]
  • 193.Krown S.E., Gold J.W.M., Niedzwiecki D. Interferon-α with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi's sarcoma associated with acquired immunodeficiency syndrome (AIDS) Ann Intern Med. 1990;112:812–821. doi: 10.7326/0003-4819-112-11-812. [DOI] [PubMed] [Google Scholar]
  • 194.Carter W.A., Brodsky I., Pellegrino M.G. Clinical, immunological, and virological effects of ampligen, a mismatched double-stranded RNA, in patients with AIDS or AIDS-related complex. Lancet. 1987;7:1286–1292. doi: 10.1016/s0140-6736(87)90543-5. [DOI] [PubMed] [Google Scholar]
  • 195.Kovacs J.A., Deyton L., Davey R. Combined zidovudine and interferon-α therapy in patients with Kaposi's sarcoma and acquired immunodeficiency syndrome (AIDS) Ann Intern Med. 1989;111:280–287. doi: 10.7326/0003-4819-111-4-280. [DOI] [PubMed] [Google Scholar]
  • 196.Zagury D., Bernard J., Cheynier R. A group specific anamnestic immune reactive against AIDS. Nature. 1988;332:728–734. doi: 10.1038/332728a0. [DOI] [PubMed] [Google Scholar]
  • 197.Zarling J., Morton P.A., Moran P.A., McClure J., Kosowski S.G., Hu S.L. T-cell responses to human AIDS virus in macaques immunized with recombinant vaccinia virus. Nature. 1986;323:344–346. doi: 10.1038/323344a0. [DOI] [PubMed] [Google Scholar]
  • 198.Furukawa K., Lotzova E., Freedman R.S., Bowen J.B., Edwards C.L., Wharton J.T. Effect of virus-modified tumour cell extracts, autologous mononuclear cell infusions and interleukin-2 on oncolytic activity of effector cells of patients with advanced ovarian cancer. Cancer Immunol Immunother. 1989;30:126–132. doi: 10.1007/BF01665964. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 199.Berman P.W., Gregory T.J., Riddle L. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp 120 but not gp 160. Nature. 1990;345:622–625. doi: 10.1038/345622a0. [DOI] [PubMed] [Google Scholar]
  • 200.Jackson G.G., Rubenis M., Knigge M. Passive immunoneutralization of human immunodeficiency virus in patients with advanced AIDS. Lancet. 1988;9:647–652. doi: 10.1016/s0140-6736(88)90468-0. [DOI] [PubMed] [Google Scholar]
  • 201.Zolla-Pazner S., Pinter A., Mizuma H. Potential use of serotherapy in the prevention and treatment of infection with the human immunodeficiency virus. J Virol Meth. 1987;17:45–53. doi: 10.1016/0166-0934(87)90067-x. [DOI] [PubMed] [Google Scholar]
  • 202.Javaherian K., Langlois A.J., McDanal C. Vol. 86. 1989. Principle neutralizing domaine of the human immunodeficiency virus type 1 envelope protein; pp. 6768–6772. (Proc Natl Acad Sci USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 203.Smith D.H., Bryn R.A., Marsters S.A., Gregory T., Groopman J.E., Capon D.J. Blocking of HIV-1 infectivity by a soluble, secreted form of CD4 antigen. Science. 1987;238:1704–1707. doi: 10.1126/science.3500514. [DOI] [PubMed] [Google Scholar]
  • 204.Bryn R.A., Mordenti J., Lucas C. Biological properties of a CD4 immunoadhesin. Nature. 1990;344:667–670. doi: 10.1038/344667a0. [DOI] [PubMed] [Google Scholar]
  • 205.Ashorn P., Moss B., Weinstein J.N. Vol. 87. 1990. Elimination of infectious human immunodeficiency virus from human T-cell cultures, by synergistic action of CD4 pseudomonas exotoxin and reverse transcriptase inhibitors; pp. 1–5. (Proc Natl Acad Sci USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 206.Barcellini W., Meroni P.L., Frasca D. Effect of subcutaneous thymopentin treatment in drug addicts with persistent generalized lymphadenopathy. Clin Exp Immun. 1987;67:537–543. [PMC free article] [PubMed] [Google Scholar]
  • 207.Silvestris F., Gernone A., Frassanito M., Dammacco F. Immunologic effect of long-term thymopentin treatment in patients with HIV-induced lymphadenopathy syndrome. J Lab Clin Med. 1989;113:139–144. [PubMed] [Google Scholar]
  • 208.Pedersen C., Sandstrom E., Peterson C.S. The efficacy of inosine paranobex in preventing the acquired immunodeficiency syndrome in patients with human immunodeficiency virus infection. N Engl J Med. 1990;322:1757–1763. doi: 10.1056/NEJM199006213222501. [DOI] [PubMed] [Google Scholar]
  • 209.Reisinger E.C., Kern P., Ernst M. Inhibition of HIV progression by ditiocarb. Lancet. 1990;335:679–682. doi: 10.1016/0140-6736(90)90802-c. [DOI] [PubMed] [Google Scholar]
  • 210.Hersh E.M., Brewton G., Abrams D. Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized double-blind placebo-controlled multicentre study. J Am Med Assoc. 1991;265:1538–1544. [PubMed] [Google Scholar]
  • 211.Patt Y.Z., Hersh E.M., Reuben J.M., Claghorn L., Mavligit G.M. A phase I study of intravenous azimexon therapy in human cancer. J Biol Resp Mod. 1986;5:313–318. [PubMed] [Google Scholar]
  • 212.Haranaka K., Satomi N., Sakurai A. Anti-tumor activities and tumor necrosis factor producibility of traditional Chinese medicines in crude drugs. Cancer Immunol Immunother. 1985;20:1–5. doi: 10.1007/BF00199765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 213.Satomi N., Sakurai A., Haranaka R., Haranaka K. The influence of antibiotics on the host-parasite relationship. Springer-Verlag; Berlin: 1988. Traditional Chinese medicines and drugs in relation to the host-defence mechanism; pp. 77–86. [Google Scholar]
  • 214.Kono H., Ohara M., Odajima S., Yamaguchi N. The effect of Saikosaponin on immune response. J Med Pharmacol Soc Wakan-Yaka. 1985;2:85–89. [Google Scholar]
  • 215.Iwama H., Amagaya, Ogihara Y. Studies of the combined use of steroid and Shosaiko-to, one of the Kanpohoza (Chinese traditional medicine), on pituitary adrenal cortical space axis funstion and immune responses. J Pharmacobiodyn. 1986;9:189–196. doi: 10.1248/bpb1978.9.189. [DOI] [PubMed] [Google Scholar]

Articles from International Journal of Antimicrobial Agents are provided here courtesy of Elsevier

RESOURCES